Analyst lifts price target on Oncolytics with new clarity from the FDA on Reolysin’s path forward to approval.
However, Aurinia’s not-so-secret lead drug asset Voclosporin offers a compelling partnering opportunity.
Valeant Pharmaceuticals Intl Inc (NYSE:VRX) posted first quarter financial results yesterday for the year that might prove the once-sinking ship might have found …
Canaccord analyst Neil Maruoka came out today with a few thoughts on Valeant Pharmaceuticals Intl Inc (NYSE:VRX), following the news that the drug maker will sell …
AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) shares are sinking 8% after the firm announced what Canaccord analyst Neil Maruoka deems “another disappointment for Macrilen,” …
Valeant Pharmaceuticals Intl Inc (NYSE:VRX) shares were falling 5% yesterday after the reveal that three high-level executives were on their way out of …
Valeant Pharmaceuticals Intl Inc (NYSE:VRX) shares stumbled over 10% in the past two days, after the Wall Street Journal reported that the deal making …
AEterna Zentaris (NASDAQ:AEZS) delivered a financial third-quarter report on Tuesday, November 8th that “modestly” underperformed Canaccord analyst Neil Maruoka‘s expectations “on a lighter …
Valeant Pharmaceuticals Intl Inc (NYSE:VRX) posted a third-quarter print yesterday that was decent in terms of revenue, but found itself missing when it …
Analyst Neil Maruoka of Canaccord raised his price target on Hold-rated Valeant Pharmaceuticals Intl Inc. (NYSE:VRX) to $33 (from $31), after the drug maker …
